HER2阳性早期乳腺癌新辅助治疗中残留病灶生物学及基因表达变化的预后价值
在CALGB 40601、PAMELA、NeoALTTO和NSABP B-41四项新辅助研究中,分析169对配对肿瘤样本发现,残留病灶内在亚型从基线HER2富集型(50.3%)向正常样型(49.1%)和luminal A型(18.9%)转变,并伴免疫激活;残留病灶免疫基因表达特征预后价值更高,最佳多变量无事件生存模型纳入残留病灶免疫球蛋白G特征(c-index=0.77)。
要点
- 残留病灶内在亚型由基线HER2富集型向正常样型和luminal A型转变。
- 残留病灶中B细胞、CD8 T细胞和自然杀伤细胞特征显著升高。
- 基线肿瘤标志物预后信息更多,残留病灶中免疫标志物预后更佳。
核心结论
- 在HER2阳性早期乳腺癌残留病灶患者中,基线时肿瘤标志物提供更多预后信息,而残留病灶中免疫标志物对无事件生存的预后更好。
研究设计与样本
- 基于CALGB 40601、PAMELA、NeoALTTO和NSABP B-41四项新辅助研究,比较肿瘤与免疫基因表达变化及其与无事件生存的关联。
- 分析452份基线残留病灶样本,其中169份有配对残留病灶样本,采用单变量和多变量Cox回归模型,并以c-index评估模型表现。
主要发现
- 169对配对肿瘤样本分析显示,内在亚型比例从基线HER2富集型(50.3%)转变为残留病灶中正常样型(49.1%),随后为luminal A型(18.9%)。
- 与HER2富集型质心的相关性降低,ERBB2及HER2扩增子基因表达下降,与luminal A型质心相关性升高(Wilcoxon检验P < 0.001)。
- 残留病灶显示相对免疫激活,B细胞、CD8 T细胞和自然杀伤细胞特征显著升高(Wilcoxon检验P < 0.05)。
- 多变量Cox模型中,基线内在亚型提供更多预后信息,而残留病灶中免疫基因表达特征提供更多预后信息。
- 最佳多变量无事件生存模型(c-index = 0.77)纳入残留病灶样本的免疫球蛋白G特征(校正风险比0.45,95%置信区间0.30-0.67,校正P = 0.002)。
关键数值与推荐
- 基线HER2富集型比例为50.3%,残留病灶中正常样型为49.1%,luminal A型为18.9%。
- 免疫球蛋白G特征的校正风险比为0.45(95%置信区间0.30-0.67,校正P = 0.002),最佳模型c-index = 0.77。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC), we investigated tumor and immune changes during neoadjuvant treatment and their impact on residual disease (RD) biology and prognostic implications across four neoadjuvant studies of trastuzumab with or without lapatinib, and with or without chemotherapy: CALGB 40601, PAMELA, NeoALTTO, and NSABP B-41. PATIENTS AND METHODS: We compared tumor and immune gene expression changes during neoadjuvant treatment and their association with event-free survival (EFS) by uni- and multivariable Cox regression models in different cohorts and timepoints: 452 RD samples at baseline including 169 with a paired RD, and biomarker changes during neoadjuvant therapy, evaluating model performance via the c-index. RESULTS: Analysis of 169 paired tumor samples revealed a shift in intrinsic subtype proportions from HER2-enriched at baseline (50.3%) to normal-like (49.1%) followed by luminal A (18.9%) in RD. This luminal phenotypic change was supported by decreased correlation to the HER2-enriched centroid, ERBB2, and HER2 amplicon genes and increased correlation to the luminal A centroid (Wilcoxon test P < 0.001). Additionally, RD showed relative immune activation marked by significant increases in B-cell, CD8 T-cell, and natural killer cell signatures (Wilcoxon test P < 0.05). In multivariable Cox models, intrinsic subtypes at baseline provided more prognostic information, while immune gene expression signatures provided more prognostic information in RD. Notably, the best multivariable EFS model (c-index = 0.77) integrated the immunoglobulin G signature from RD samples (adjusted hazard ratio 0.45, 95% confidence interval 0.30-0.67, adjusted P = 0.002). CONCLUSIONS: In patients with HER2-positive EBC and RD, tumor biomarkers provide more prognostic information at baseline. In contrast, immune biomarkers perform better for EFS prognosis in RD.
引用
- Fernandez-Martinez A, Tanioka M, Ahn SG, et al. Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC). Ann Oncol. 2024. PMID: 39706338. doi:10.1016/j.annonc.2024.12.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。